# Major Recall Alert: Chlorpromazine Hydrochloride Tablets, USP 10 mg, 100’s Count, Gabapentin Capsules, Propafenone Hydrochloride ER Capsules, Solifenacin Succinate Tablets, Voriconazole Tablets, Lacosamide, Frovatriptan Succinate, and Rufinamide Tablets Recalled Due to Manufacturing Issues, CGMP Deviations, Contamination Risks, and Harmful Impurities
Leading pharmaceutical brands Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, and Zydus Pharmaceuticals have issued a significant recall involving various medications. This is due to concerning manufacturing-related problems, Current Good Manufacturing Practice (CGMP) deviations, cross-contamination risks, and the potential presence of harmful impurities. Learn more about this critical health alert and what steps you should take to stay safe.
## Why This Recall is Important
Product recalls, particularly for essential medications, can have significant health, safety, and supply chain implications. The medications included in this recall are commonly prescribed for various chronic and acute medical conditions, making vigilance crucial.
The issues identified—such as CGMP violations and cross-contamination—signal a breach in quality control standards required to ensure drug safety and efficacy. Harmful impurities, if consumed, could pose serious health risks, especially for vulnerable populations like the elderly, children, and individuals with compromised immune systems.
## Details of the Recall
### Impacted Products:
- **Chlorpromazine Hydrochloride Tablets, USP 10 mg, 100’s Count**
- **Gabapentin Capsules**
- **Propafenone Hydrochloride ER Capsules**
- **Solifenacin Succinate Tablets**
- **Voriconazole Tablets**
- **Lacosamide**
- **Frovatriptan Succinate**
- **Rufinamide Tablets**
### Recall Reasons:
- **Manufacturing-related Problems**: Defects in the production process have impacted product quality.
- **CGMP Deviations**: Failure to meet established regulatory standards for pharmaceutical manufacturing.
- **Cross-contamination Risks**: Potential exposure of products to unintended substances.
- **Harmful Impurities Detected**: Impurities that could pose risks to consumer health were found in the affected products.
### Date Announced:
This alert, issued under Public Alert No. 11/2025, highlights the urgent safety concern. For official updates, visit the [NAFDAC website](https://nafdac.gov.ng/public-alert-no-11-2025-recall-of-various-products-by-sun-pharma-glenmark-and-zydus-pharmaceuticals-over-manufacturing-issues/).
## What You Should Do
If you use any of the recalled products, please follow these steps immediately to safeguard your health:
- **Stop Using the Affected Medications**: Discontinue use and consult your doctor for alternatives.
- **Report Suspected Issues**: If you suspect that you may have received substandard or falsified medicines, contact NAFDAC immediately through their approved channels.
- **Verify Source of Purchase**: Always obtain medical products from authorized/licensed suppliers to minimize safety risks.
### NAFDAC Contact Information:
For inquiries or to report safety concerns, reach out to NAFDAC directly. Visit [NAFDAC’s official website](https://nafdac.gov.ng/) for more details.
## Stay Safe – Get Instant Recall Alerts
Health and safety are priorities, especially when it comes to medication. To stay informed about recalls and protect your family:
- **Download NAFDAC’s Official App**: Receive real-time updates on recalls, safety alerts, and other public health-related announcements.
- **Subscribe to Alerts**: Sign up for email or text notifications for important pharmaceutical and safety updates.
This recall highlights the importance of vigilance in the pharmaceutical supply chain. Share this information with your loved ones, and ensure that your medications are safe and high-quality. Stay proactive in your healthcare journey and always prioritize safety.
For detailed information on this recall, view the official announcement [here](https://nafdac.gov.ng/public-alert-no-11-2025-recall-of-various-products-by-sun-pharma-glenmark-and-zydus-pharmaceuticals-over-manufacturing-issues/).
Stay informed, stay safe.